跳至主要内容
临床试验/JPRN-UMIN000001993
JPRN-UMIN000001993已完成未知

Effects of rosuvastatin and ezetimibe on bone turnover markers in type 2 diabetes patients with hypercholesterolemia - Effects of rosuvastatin and ezetimibe on bone turnover markers

Department of Internal Medicine 1, Shimane University School of Medicine0 个研究点目标入组 40 人开始时间: 2009年5月21日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
40

研究概览

简要总结

Serum osteocalcin levels in the rosuvastatin group were significantly increased, while any bone marker in the ezetimibe group was not changed.

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Nobody had hepatic or renal dysfunction or nutritional derangements. All patients were free of drugs known to influence bone and calcium metabolism, such as vitamin D, bisphosphonate, or estrogen, up until the time of the study. Nobody had treatments with any cholesterol lowering agent.

研究者

发起方
Department of Internal Medicine 1, Shimane University School of Medicine

相似试验